Sarepta Therapeutics layoffs, on the record
Every job cut, severance charge and restructuring Sarepta Therapeutics reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from 1,314 to 1,372.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | 1,314 | As of December 31, 2023 |
| 10-K for 2024 | 1,372 | December 31, 2024 |
Job cuts, severance and restructuring
Our summaryAnnounced a strategic restructuring plan with a revised cost structure, a changed program portfolio and a reduction in force.
Word for word“In July 2025, we announced a strategic restructuring plan, which included a revised cost structure and program portfolio and a reduction in force.” 10-K for 2025
Our summaryThe workforce reduction cut about 36% of the company's workforce at the time it was implemented.
Word for word“The workforce reduction represented approximately 36% of our workforce at the time it was implemented.” 10-K for 2025
Our summaryRecorded a restructuring charge for 2025, with none in 2024.
Word for word“Cost and expenses: Cost of sales (excluding amortization of in-licensed rights) 839,605 319,099 520,506 163 % Research and development 1,522,066 804,522 717,544 89 % Selling, general and administrative 491,716 557,872 (66,156 ) (12 )% Restructuring charge 42,009 — 42,009 * Amortization of in-licensed rights 2,622 2,405 217 9 % Total cost and expenses 2,898,018 1,683,898 1,214,120 72 % Operating (loss) income (699,781 ) 218,081 (917,862 ) * Other (loss) income, net: Other (expense) income, net (19,306 ) 42,693 (61,999 ) (145 )% Gain on debt extinguishment 16,862 — 16,862 * Total other (loss) income, net (2,444 ) 42,693 (45,137 ) * (Loss) income before income tax expense (702,225 ) 260,774 (962,999 ) * Income tax expense 11,185 25,535 (14,350 ) (56 )% Net (loss) income $ (713,410 ) $ 235,239 $ (948,649 ) * (Loss) earnings per share: Basic $ (7.13 ) $ 2.47 $ (9.60 ) * Diluted $ (7.13 ) $ 2.34 $ (9.47 ) * *Not meaningful Revenues Revenues from product sales are recorded at the time of sale at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from rebates, governmental chargebacks including PHS chargebacks, prompt pay discounts, patient assistance programs and distribution fees.” 10-K for 2025
| Fiscal year ended | Severance costs | Restructuring charges | Cash paid for restructuring |
|---|---|---|---|
| 2016-12-31 | — | $3.7 million | $2.1 million |
| 2017-12-31 | — | $3 million | $1.7 million |
| 2018-12-31 | — | — | $711,000 |
| 2023-12-31 | — | $0 | — |
| 2024-12-31 | — | $0 | — |
| 2025-12-31 | $34.9 million | $42 million | — |
Sarepta Therapeutics filed 2 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Sarepta Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-03-02. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.